Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
2 hedge funds and large institutions have $1.13M invested in Global X China Biotech Innovation ETF in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
25% less capital invested
Capital invested by funds: $1.52M → $1.13M (-$386K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$18.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$479K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1.11M | -$479K | -30,570 | -31% |
|
|
2
UBS Group
Zurich,
Switzerland
| $20K | +$18.9K | +1,205 | New |
|
CHB Hedge Fund Activity: Q4 2020 in Review
2 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q4 2020, worth a combined $1.13M — down 25% from $1.52M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CHB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $18.9K. The largest seller was Susquehanna International Group, cutting an estimated $479K.
- 2 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q4 2020, up from 1 in Q3 2020.
- Funds reported $1.13M of Global X China Biotech Innovation ETF stock for Q4 2020, down 25% quarter-over-quarter.
- 1 fund opened new Global X China Biotech Innovation ETF positions in Q4 2020 and 0 closed out, a net change of +1 holder.
- The largest Global X China Biotech Innovation ETF buyer in Q4 2020 was UBS Group, an estimated $18.9K added.
- The largest Global X China Biotech Innovation ETF seller in Q4 2020 was Susquehanna International Group, an estimated $479K sold.
Based on aggregated 13F filings for Q4 2020.